Full Breakdown
Absci Partners with Oracle and AMD to Enhance AI-Driven Drug Discovery
9/12/2025, 12:52:35 PM
Collaboration Overview
On September 11, 2025, Absci, a clinical-stage biotech company, announced a strategic collaboration with Oracle Cloud Infrastructure (OCI) and AMD to enhance its generative AI-driven drug discovery capabilities. This partnership aims to accelerate the design and development of biologics by leveraging OCI's advanced AI infrastructure and AMD's cutting-edge hardware, specifically the next-generation Instinct™ MI355X GPUs. The collaboration is expected to significantly shorten drug design cycles and reduce costs associated with drug discovery.
Technological Integration
Absci has selected OCI as the foundational platform for developing and scaling its AI models, which include large-scale molecular-dynamics simulations and comprehensive antibody design workflows. The integration of OCI's bare-metal instances, powered by 5th Generation AMD EPYC™ processors, provides Absci with low-latency networking and high throughput essential for training large models. This setup allows for inter-GPU latency as low as 2.5 microseconds and enables terabytes-per-second data streaming, which are critical for refining antibody-antigen interactions.
Official Statements & Responses
Sean McClain, Founder and CEO of Absci, emphasized the mission to "push the boundaries of how we design new therapeutics," highlighting the importance of pairing advanced AI models with robust infrastructure. Dan Spellman, Vice President of AI and OCI at Oracle, noted that Absci's generative AI-driven drug discovery exemplifies the breakthrough workflows OCI was designed to support. Similarly, Ram Peddibhotla, Corporate Vice President at AMD, remarked on the collaboration's potential to transform the pace of drug discovery.
Criticism & Opposition
Despite the promising collaboration, some industry observers express concerns regarding Absci's reliance on external partnerships for its drug discovery processes. This dependency may raise questions about the company's technological independence and long-term strategic viability. Additionally, skepticism exists within the biotech community about the efficacy and safety of AI-generated therapeutics compared to traditional methods.
Why It Matters
This collaboration underscores a significant trend in the biotech sector, where cloud infrastructure and advanced GPU technology are increasingly utilized to enhance AI workloads. The partnership not only positions Absci to expedite the development of novel therapeutics but also reflects broader implications for the semiconductor and cloud computing industries, particularly in Europe and beyond.
Verbatim Quotes
- “Our mission is to push the boundaries of how we design new therapeutics,” — Sean McClain, Founder and CEO, Absci
- “Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for,” — Dan Spellman, Vice President, AI and OCI, Oracle
What's Next
As Absci continues to develop its AI Drug Creation Platform, the company plans to participate in several investor conferences to showcase its progress in AI-powered drug discovery. The outcomes of this collaboration may set new benchmarks in the biotech industry, influencing future partnerships and technological advancements in drug development.
